- The FDA approves the use of GlaxoSmithKline's (GSK +0.6%) Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis, a rare autoimmune disorder that causes blood vessel inflammation.
-
Nucala was first approved in the U.S. in 2015 for eosinophilic asthma.